Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia: A Children’s Oncology Group Pilot Study Report

Patient-specific primers from 10 children/adolescents with Burkitt leukaemia (BL) ± central nervous system disease who were treated with French-British-American/Lymphome Malins de Burkitt 96 C1 plus rituximab were developed from diagnostic blood/bone marrow. Minimal residual disease (MRD) was assess...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Br J Haematol
Päätekijät: Shiramizu, Bruce, Goldman, Stanton, Smith, Lynette, Agsalda-Garcia, Melissa, Galardy, Paul, Perkins, Sherrie L., Frazer, J. Kimble, Sanger, Warren, Anderson, James R., Gross, Thomas G., Weinstein, Howard, Harrison, Lauren, Barth, Matthew J., Mussolin, Lara, Cairo, Mitchell S.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2015
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4503484/
https://ncbi.nlm.nih.gov/pubmed/25858645
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.13443
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia